Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 1
Submit an article Journal homepage
129
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived

Sara Farshchi ZarabiPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaORCID Iconhttp://orcid.org/0000-0003-3478-9663View further author information
ORCID Icon,
Steven ChanPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Vikas GuptaPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Dina KhalafPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Andrzej LutynskiPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Mark D. MindenPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Amr RostomPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Anna RydlewskiPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Andre C. SchuhPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Hassan SibaiPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Karen W. L. YeePrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
&
Aaron D. SchimmerPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaCorrespondence[email protected]
View further author information
 show all
Pages 237-240 | Received 17 Jan 2017, Accepted 22 Apr 2017, Published online: 09 Jun 2017

References

  • Walter RB, Othus M, Burnett AK, et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia. 2015;29:312–320.
  • Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
  • Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? JCO. 2016;34:329–336.
  • Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730–3738.
  • Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood. 2011;117:2307–2318.
  • Jabbour E, Daver N, Champlin R, et al. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014;89:395–398.
  • Fung HC, Stein A, Slovak M, et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant. 2003;9:766–771.
  • Roboz GJ, Rosenblat T, Arellano M, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. JCO. 2014;32:1919–1926.
  • Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
  • Mrozek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. JCO. 2012;30:4515–4523.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.